AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

FTH · NASDAQ · Biotechnology

Faeth Therapeutics

Develops PIKTOR, an oral cancer regimen designed to block multiple PAM-pathway nodes.

$33.84

After-hours close+0.16 (+0.48%)

At close$33.68(−0.18%)

Something off on this page? Send us feedback.

Profile

Faeth Therapeutics, Inc.FTHHealth Care

Develops PIKTOR, an investigational oral cancer regimen combining serabelisib and sapanisertib, while advancing preclinical NEAAR and IEM programs. With no product revenue or commercial sales organization, its model finances clinical development while relying on licensed rights and external research, trial, and manufacturing partners.

Develops cancer therapeutics around PIKTOR, an investigational oral combination of serabelisib and sapanisertib that targets several points in the PI3K/AKT/mTOR pathway. Its clinical programs study PIKTOR in advanced endometrial cancer and HR-positive/HER2-negative advanced breast cancer; its earlier work includes the preclinical NEAAR and IEM programs. Based in Austin, Texas, it has development rights for PIKTOR components worldwide within licensed fields.

Runs a focused, pre-revenue development model, relying on CROs, clinical sites, consultants, suppliers, and contract manufacturers rather than a commercial sales organization. Progress depends on clinical evidence, regulatory approval, reliable supply of both active ingredients, licensed rights from Takeda and Millennium Takeda, and external execution.

Company facts

CEOAnand Parikh

ListedJun 16, 2026

ExchangeNASDAQ

HeadquartersAustin, TX

CountryUnited States

Employees29

CIK0001829802

ISINUS81728A2078

Key statistics

Market cap$872.4M

EPS (ttm)−$141.65

P/E (ttm)−0.2389

ROE-192.8%

P/B1.10

P/S−179.83

Dividend yield—

Beta2.00vs XLV −0.23

Year to date +249% · Average volume (30d) 299.4K

Analysts

Price target, next 12 months$56.50+67.0%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy5 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $33.84

High$60.00+77.3%

Median$56.50+67.0%

Low$50.00+47.8%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Target
Aug 21, 2026	Needham	Initiate	Buy	$56
Jul 31, 2026	Raymond James	Initiate	Outperform	$56
Jul 27, 2026	Oppenheimer	Initiate	Outperform	$60
Jul 20, 2026	Citigroup	Initiate	Outperform
Jun 25, 2026	Robert W. Baird	Target		$57

Earnings

EPS

Estimate−$0.66

ReportedDue Nov 13, 2026

Revenue

Estimate—

ReportedDue Nov 13, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 4, 2026Q2 FY26	−$2.64	−$2.84	−7.6%	—	—	—	−6.73%
May 15, 2026Q1 FY26	−$0.62	−$131.45	−21,101.6%	—	—	—	−2.55%
Mar 30, 2026Q4 FY25	−$4.81	−$3.74	+22.2%	—	—	—	+25.43%
Nov 14, 2025Q3 FY25	−$4.11	−$3.62	+11.9%	—	−$4.9M	—	+1.62%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	−$4.9M	$0	$0	$0
Gross profit	$0	$0	$0	$0	−$133.0M	$0
Operating income	−$7.3M	−$5.2M	−$4.9M	−$5.0M	−$170.6M	−$18.4M
Net income	−$6.9M	−$4.9M	−$4.6M	−$4.7M	−$170.2M	−$16.0M
Diluted EPS	−$5.45	−$3.91	−$3.62	−$3.74	−$131.45	−$2.84
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY24 $0 · FY25 −$4.9M

Balance sheet, Jun 30, 2026Cash & short-term investments $186.4M · Total debt $592.0K · Total assets $189.3M · Shareholders' equity $173.0M

Dividends

No dividends on record.

Ownership

Institutions —Insiders —

Shares outstanding 25.78M · Float 18.61M

This issuer lists more than one class and the share count spans them all, so a stake here reads as a share of the whole company, not of this class.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% of company	Form	Filed
S2G Investments, LLC	2.58M	9.99% of class	13G	Jun 23, 2026
Suvretta Capital Management, LLC	2.02M	7.80% of class	13G	Jun 23, 2026
Khosla Ventures VI, LP	1.64M	6.40% of class	13G	Aug 14, 2026

Insider tradesForm 4

Nothing filed in the last 12 months.